LQDA
$36.41-0.95 (-2.54%)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostin...
Recent News
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset
NVS bets $2B upfront on SNV4818 to expand precision oncology in breast cancer, targeting a large mutation-driven market and boosting long-term pipeline growth.
Best Low-Beta Stocks to Own Right Away: AGRO, PRA, E & LQDA
Low-beta picks gain focus as Iran war fears stir volatility. AGRO, PRA, E and LQDA reflect resilience with momentum, liquidity and fundamentals.
Can Liquidia Corporation (LQDA) Run Higher on Rising Earnings Estimates?
Liquidia Corporation (LQDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts See a 35.35% Upside in Liquidia Corporation (LQDA): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 35.4% in Liquidia Corporation (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why Liquidia (LQDA) Is Down 5.1% After Swing to Profit and $125 Million Shelf Filings
In March 2026, Liquidia Corporation reported that fourth-quarter 2025 revenue rose to US$92.02 million from US$2.92 million a year earlier, swinging from a net loss to net income of US$14.56 million and positive earnings per share. On the same day, the company also filed multiple shelf registrations covering common and preferred stock, debt, warrants, and ESOP-related common share offerings totaling over US$125 million, highlighting an intention to access fresh capital alongside its...